Generic Medicine Info
Delayed-release: May be taken with or without food.
Concomitant use with rilpivirine.
Special Precautions
Patients at risk of osteoporosis, reduced body stores or with risk factors for vitamin B12 malabsorption, PPI-induced autoimmune disease. Severe hepatic impairment. Children and elderly. Pregnancy and lactation. Patient Counselling This drug may cause somnolence, if affected, do not drive or operate machinery. Monitoring Parameters Monitor magnesium levels prior to initiation of therapy and periodically thereafter on long-term treatments or in patients taking digoxin, diuretics or other drugs that cause hypomagnesaemia.
Adverse Reactions
Significant: New-onset or exacerbation of subacute cutaneous and systemic lupus erythematosus, osteoporosis-related bone fractures, fundic gland polyps, acute interstitial nephritis, Clostridium difficile-associated diarrhoea (hospitalised patients). Rarely, hypomagnesaemia, vitamin B12 deficiency. Gastrointestinal disorders: Diarrhoea, vomiting, nausea, abdominal pain, constipation, flatulence. General disorders and administration site conditions: Back pain, asthenia, influenza-like illness. Hepatobiliary disorders: Hepatic encephalopathy, hepatitis. Infections and infestations: Infection (e.g. Salmonella, Campylobacter). Investigations: Increased liver enzymes. Nervous system disorders: Headache, dizziness. Psychiatric disorders: Insomnia. Respiratory, thoracic and mediastinal disorders: Cough, pharyngitis, rhinitis.
Drug Interactions
May decrease serum concentration of ketoconazole, itraconazole, atazanavir, nelfinavir. Increased INR and prothrombin time with concomitant use of warfarin. Increased serum concentrations of methotrexate, tacrolimus, saquinavir.
CIMS Class
Antacids, Antireflux Agents & Antiulcerants
ATC Classification
A02BC04 - rabeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Disclaimer: This information is independently developed by CIMS based on rabeprazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in